← BeiGene overview
BeiGene Ltd.688235.CG

Why is BeiGene (688235.CG) moving?

Q3 2026
▲4

BeiGene's BRUKINSA Wins, Profit Surge, US Expansion Drive Q3

  • BRUKINSA Phase 3 wins and soaring sales BRUKINSA won Phase 3 trials in two blood cancers and sales jumped to $3.9 billion, fueling growth. This success is the main engine behind BeiGene's strong performance.

    It explains the core revenue and pipeline driver for the quarter.

  • First full-year profit and record H1 earnings BeiGene reported its first full-year profit and record first-half results: net profit soared 627% to RMB 3.27 billion and revenue rose 26.8%, with raised guidance.

    It highlights the financial turnaround that boosted investor confidence.

  • $300 million US manufacturing expansion secures tariff exemption A $300 million investment in US manufacturing secured a tariff exemption, removing a major cost risk and supporting US market access.

    It addresses a key regulatory and cost concern that could have hurt profitability.

  • Revolution Medicines collaboration broadens pipeline A new collaboration with Revolution Medicines expands BeiGene's pipeline beyond BRUKINSA, helping diversify future growth sources.

    It shows progress in reducing reliance on a single drug.

August 2026
▲4

BeiGene Surges on Strong H1 Results and Tariff Relief

  • Record H1 2026 Earnings BeiGene reported H1 2026 net profit up 627% to RMB 3.27bn, with revenue rising 26.8% to RMB 22.22bn. Q2 revenue grew 30% and BRUKINSA sales topped $1.2bn, showcasing robust demand and operational leverage.

    This is the primary new financial catalyst that drove the stock in August.

  • Raised Full-Year Guidance Management increased full-year revenue guidance, citing strong global demand for BRUKINSA. This signals confidence in continued growth and supports higher investor expectations for future performance.

    Guidance raise is a new forward-looking positive that directly influences valuation.

  • US Tariff Exemption Secured BeiGene secured an exemption from US tariffs by committing to US manufacturing. This removes a major cost risk and protects US sales, which are crucial for BRUKINSA's growth.

    Tariff exemption is a new regulatory development that de-risks US operations.

  • New Pipeline Collaboration BeiGene announced a collaboration with Revolution Medicines, adding pipeline potential. This expands future growth opportunities beyond BRUKINSA and enhances the company's long-term prospects.

    New partnership is a fresh strategic move that could drive future value.

Latest
▲4

BeiGene's profit surge and US tariff exemption drive gains

  • Q2 revenue up 30%, full-year guidance raised BeiGene's second-quarter global revenue rose 30% to $1.7 billion, and the company lifted its full-year revenue outlook to $6.6–6.8 billion. This tells investors demand for its cancer drugs is strong and future sales will likely be higher than previously expected, pushing the stock up.

    This is a new, concrete financial update that directly raises expectations for future revenue and profit.

  • First-half net profit jumps 627% Preliminary first-half results show revenue up 26.8% to 22.22 billion yuan and net profit up 627% to 3.271 billion yuan. The huge profit jump shows the company has moved from losses to solid profitability, which makes the stock more attractive to investors.

    This is a new earnings milestone that confirms a sharp turnaround in profitability, a key driver for the stock.

  • US tariff exemption and access deal BeiGene signed a voluntary agreement with the U.S. government to expand cancer drug access and secured an exemption from Section 232 pharmaceutical tariffs by committing to U.S. manufacturing. This removes a major cost risk and opens the door to more U.S. sales, lifting the stock.

    This is a new regulatory and trade development that reduces uncertainty and supports future U.S. revenue.

  • Strong cash flow and sector momentum The interim report showed 4.439 billion yuan of operating cash inflow, and BeiGene was highlighted in a broad innovative-drug rally. Strong cash generation funds research and expansion, while sector enthusiasm can attract more buyers to the stock.

    This combines new cash-flow data with sector momentum that supports investor interest in the stock.

▲4

BeiGene Profit Surges 627%, Guidance Raised on BRUKINSA Strength

  • First-Half Profit Jumps 627%, Full-Year Revenue Guidance Raised BeiGene's first-half net profit rose 627% to 3.27 billion yuan, with revenue up 26.8% to 22.22 billion yuan. The company raised its 2026 revenue forecast to 44.9–46.2 billion yuan, signaling stronger-than-expected demand for its drugs and boosting investor confidence.

    This is the core new financial result that directly drives the stock higher by showing accelerating profitability and raised outlook.

  • Q2 Revenue Up 30%, BRUKINSA Sales Exceed $1.2 Billion BeiGene's subsidiary BeOne Medicines reported Q2 revenue of $1.7 billion, up 30%, with BRUKINSA global sales exceeding $1.2 billion. The company raised its 2026 revenue guidance by $300 million and operating income guidance by $250 million, reflecting strong global demand.

    This provides a more recent quarterly update that reinforces the growth trajectory and raises full-year targets, directly supporting the stock price.

  • Sector-Wide Rally in Innovative Drugs Lifts BeiGene China's pharmaceutical sector has been rallying, with multiple stocks hitting daily limit-ups. Analysts say this rally may be more durable than previous ones, driven by strong interim results and global expansion. BeiGene's positive results contribute to the sector resonance, attracting capital inflows.

    This explains the broader market sentiment and capital rotation into pharma that is lifting BeiGene's stock alongside its own strong results.

  • New Collaboration with Revolution Medicines Adds Pipeline Potential On August 10, BeiGene announced a collaboration with Revolution Medicines, part of a wave of Chinese pharma global expansion deals. This partnership could bring new pipeline assets and validates BeiGene's research capabilities, offering a potential future growth driver.

    This is a new strategic development that could enhance BeiGene's long-term pipeline and global reach, positively impacting investor sentiment.

July 2026
▲4

BeiGene's BRUKINSA Data and US Expansion Drive Growth

  • BRUKINSA Phase 3 Wins in Two Blood Cancers New Phase 3 data show BRUKINSA helps patients live longer without their cancer worsening in two types of blood cancer. This strengthens its position as a top treatment, supporting future sales growth and making the stock more attractive.

    These clinical wins directly boost confidence in BeiGene's key drug and future revenue.

  • BeiGene Achieves First Full-Year Profit BeiGene reached its first full-year profit, a major milestone that shows the company is now financially sustainable. This attracts investors who previously worried about losses and supports a higher stock price.

    Profitability is a fundamental shift that improves the investment case.

  • US Manufacturing Expansion to Avoid Tariffs BeiGene is investing an extra $300 million to expand its US factory, which will make drugs locally and help avoid a potential 100% tariff on imported medicines. This protects profits and ensures supply for the important US market.

    This move reduces regulatory and cost risks, directly supporting future earnings.

  • Zanubrutinib Sales Soar to $3.9 Billion BeiGene's main drug, zanubrutinib, saw global sales jump from $1 billion to $3.9 billion, with most revenue from the US. This proves strong demand and successful commercialization, driving the stock higher.

    Strong sales growth is a direct driver of revenue and investor confidence.

▲4

BeiGene's BRUKINSA Data and US Expansion Drive Growth

  • BRUKINSA Phase 3 Wins in Two Blood Cancers New Phase 3 data show BRUKINSA helps patients live longer without their cancer worsening in two types of blood cancer. This strengthens its position as a top treatment, supporting future sales growth and making the stock more attractive.

    These clinical wins directly boost confidence in BeiGene's key drug and future revenue.

  • BeiGene Achieves First Full-Year Profit BeiGene reached its first full-year profit, a major milestone that shows the company is now financially sustainable. This attracts investors who previously worried about losses and supports a higher stock price.

    Profitability is a fundamental shift that improves the investment case.

  • US Manufacturing Expansion to Avoid Tariffs BeiGene is investing an extra $300 million to expand its US factory, which will make drugs locally and help avoid a potential 100% tariff on imported medicines. This protects profits and ensures supply for the important US market.

    This move reduces regulatory and cost risks, directly supporting future earnings.

  • Zanubrutinib Sales Soar to $3.9 Billion BeiGene's main drug, zanubrutinib, saw global sales jump from $1 billion to $3.9 billion, with most revenue from the US. This proves strong demand and successful commercialization, driving the stock higher.

    Strong sales growth is a direct driver of revenue and investor confidence.